Skip to main content
Top
Published in: Tumor Biology 5/2011

01-10-2011 | Research Article

Involvement of ERK1/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620

Authors: Donglin Guo, Hong Zhou, Ying Wu, Fang Zhou, Guoying Xu, Haiping Wen, Xianmei Zhang

Published in: Tumor Biology | Issue 5/2011

Login to get access

Abstract

Our previous study has demonstrated that TF/FVIIa and protease-activated receptor 2 (PAR2) are closely related to the proliferation and migration of colon cancer cell line SW620. However, the detailed signaling cascades and underlying molecular mechanisms remain unclear. This study has investigated whether extracellular signal-regulated kinase 1 and 2 (ERK1/2) and nuclear factor kappaB (NF-κB) signaling pathways are involved in the events. The results revealed that PAR2-activating peptide (PAR2-AP) or FVIIa elicited time-dependent upregulation of ERK1/2 phosphorylation in SW620 cells, and the effect of FVIIa was significantly attenuated by anti-TF antibody. PAR2-AP or FVIIa also increased NF-κB (p65/RelA) levels among cell nuclear proteins and simultaneously decreased IκB-α levels in the cytoplasmic proteins. Such effects of FVIIa can be inhibited with anti-PAR2 or anti-TF antibodies. While ERK1/2 inhibitor (U0126) intervened with the regulatory effects of PAR2-AP and FVIIa on IκB-α/NF-κB (p65/Rel) expression in the cells, NF-κB inhibitor (PDTC) partially blocked the enhancing effects of PAR2-AP and FVIIa on the proliferating and migratory ability of SW620 cells. Furthermore, the regulatory effects of PAR2-AP and FVIIa on expressions of certain proteins (IL-8, caspase-7, and TF) were also significantly abolished by PDTC. Collectively, the data in this study suggest that the interaction between FVIIa and TF induces PAR2 activation, thereby triggers the ERK1/2 and IκB-α/NF-κB signal transduction pathway to regulate the gene expression of IL-8, TF, and caspase-7, and ultimately promotes SW620 cell proliferation and migration.
Literature
1.
go back to reference Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687–93.PubMedCrossRef Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007;27:1687–93.PubMedCrossRef
2.
go back to reference Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol. 2009;29:1999–2004.PubMedCrossRef Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol. 2009;29:1999–2004.PubMedCrossRef
3.
go back to reference Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103:3029–37.PubMedCrossRef Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103:3029–37.PubMedCrossRef
4.
go back to reference Rao LV, Pendurthi UR. Tissue factor–factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005;25:47–56.PubMed Rao LV, Pendurthi UR. Tissue factor–factor VIIa signaling. Arterioscler Thromb Vasc Biol. 2005;25:47–56.PubMed
5.
go back to reference Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase activated receptors. Pharmacol Rev. 2001;53:245–82.PubMed Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase activated receptors. Pharmacol Rev. 2001;53:245–82.PubMed
6.
go back to reference Kirkland JG, Cottrell GS, Bunnett NW, Corvera CU. Agonists of protease- activated receptors 1 and 2 stimulate electrolyte secretion from mouse gallbladder. Am J Physiol Gastrointest Liver Physiol. 2007;293:G335–46.PubMedCrossRef Kirkland JG, Cottrell GS, Bunnett NW, Corvera CU. Agonists of protease- activated receptors 1 and 2 stimulate electrolyte secretion from mouse gallbladder. Am J Physiol Gastrointest Liver Physiol. 2007;293:G335–46.PubMedCrossRef
7.
go back to reference Zhou H, Hu H, Shi W, Ling S, Wang T, Wang H. The expression and the functional roles of tissue factor and protease-activated receptor-2 on SW620 cells. Oncol Rep. 2008;20:1069–76.PubMed Zhou H, Hu H, Shi W, Ling S, Wang T, Wang H. The expression and the functional roles of tissue factor and protease-activated receptor-2 on SW620 cells. Oncol Rep. 2008;20:1069–76.PubMed
8.
go back to reference Zhou H, Shi W, Zhou B, Guo D, Wang T. Tissue factor-factor VIIa regulates interleukin-8, tissue factor and caspase-7 expression in SW620 cells through protease-activated receptor-2 activation. Mol Med Rep. 2010;3:269–74. Zhou H, Shi W, Zhou B, Guo D, Wang T. Tissue factor-factor VIIa regulates interleukin-8, tissue factor and caspase-7 expression in SW620 cells through protease-activated receptor-2 activation. Mol Med Rep. 2010;3:269–74.
9.
go back to reference Adam E, Hansen KK, Astudillo Fernandez O, Coulon L, Bex F, Duhant X, et al. The house dust mite allergen Der p 1, unlike Derp 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activatereceptor-2-independent mechanism. J Biol Chem. 2006;281:6910–23.PubMedCrossRef Adam E, Hansen KK, Astudillo Fernandez O, Coulon L, Bex F, Duhant X, et al. The house dust mite allergen Der p 1, unlike Derp 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activatereceptor-2-independent mechanism. J Biol Chem. 2006;281:6910–23.PubMedCrossRef
10.
go back to reference Chang CJ, Hsu LA, Ko YH, Chen PL, Chuang YT, Lin CY, et al. Thrombin regulates matrix metalloproteinase-9 expression in human monocytes. Biochem Biophys Res Commun. 2009;385:241–6.PubMedCrossRef Chang CJ, Hsu LA, Ko YH, Chen PL, Chuang YT, Lin CY, et al. Thrombin regulates matrix metalloproteinase-9 expression in human monocytes. Biochem Biophys Res Commun. 2009;385:241–6.PubMedCrossRef
11.
go back to reference Park GH, Jeon SJ, Ryu JR, Choi MS, Han SH, Yang SI, et al. Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes. Nitric Oxide. 2009;21:110–9.PubMedCrossRef Park GH, Jeon SJ, Ryu JR, Choi MS, Han SH, Yang SI, et al. Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes. Nitric Oxide. 2009;21:110–9.PubMedCrossRef
12.
go back to reference Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem. 2006;281:11792–804.PubMedCrossRef Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem. 2006;281:11792–804.PubMedCrossRef
13.
go back to reference Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.PubMedCrossRef Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310.PubMedCrossRef
14.
go back to reference Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol. 2011;21:10–20.PubMedCrossRef Min L, He B, Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol. 2011;21:10–20.PubMedCrossRef
15.
go back to reference Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E. The roles of MAPKs in disease. Cell Res. 2008;18:436–42.PubMedCrossRef Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E. The roles of MAPKs in disease. Cell Res. 2008;18:436–42.PubMedCrossRef
16.
go back to reference Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21–44.PubMedCrossRef Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21–44.PubMedCrossRef
17.
go back to reference Wang S, Liu Z, Wang L, Zhang X. NF-kappa B signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6:327–34.PubMedCrossRef Wang S, Liu Z, Wang L, Zhang X. NF-kappa B signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6:327–34.PubMedCrossRef
18.
go back to reference Caamano J, Hunter CA. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev. 2002;15:414–29.PubMedCrossRef Caamano J, Hunter CA. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev. 2002;15:414–29.PubMedCrossRef
19.
go back to reference Bonizzi G, Karin M. The two NF-kappa B activation path ways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280–8.PubMedCrossRef Bonizzi G, Karin M. The two NF-kappa B activation path ways and their role in innate and adaptive immunity. Trends Immunol. 2004;25:280–8.PubMedCrossRef
20.
go back to reference Sun SC, Ley SC. New insights into NF-κB regulation and function. Trends Immunol. 2008;29:469–78.PubMedCrossRef Sun SC, Ley SC. New insights into NF-κB regulation and function. Trends Immunol. 2008;29:469–78.PubMedCrossRef
21.
go back to reference Yang TT, Xue TY, Xu W. Reversal effect of nuclear factor-κB protease inhibitor PDTC on multidrug resistance of K562/AO cells and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:903–8.PubMed Yang TT, Xue TY, Xu W. Reversal effect of nuclear factor-κB protease inhibitor PDTC on multidrug resistance of K562/AO cells and its mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:903–8.PubMed
23.
go back to reference Petersen LC, Freskgård P, Ezban M. Tissue factor-dependent factor VIIa signaling. Trends Cardiovasc Med. 2000;10:47–52.PubMedCrossRef Petersen LC, Freskgård P, Ezban M. Tissue factor-dependent factor VIIa signaling. Trends Cardiovasc Med. 2000;10:47–52.PubMedCrossRef
24.
go back to reference Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 2003;9:5339–45.PubMed Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 2003;9:5339–45.PubMed
25.
go back to reference Lindholm PF, Lu Y, Adley BP, Vladislav T, Jovanovic B, et al. Role of monocyte-lineage cells in prostate cancer cell invasion and tissue factor expression. Prostate. 2010;70:1672–82.PubMedCrossRef Lindholm PF, Lu Y, Adley BP, Vladislav T, Jovanovic B, et al. Role of monocyte-lineage cells in prostate cancer cell invasion and tissue factor expression. Prostate. 2010;70:1672–82.PubMedCrossRef
26.
go back to reference Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000;83:164–70.PubMedCrossRef Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000;83:164–70.PubMedCrossRef
27.
go back to reference Jahan I, Fujimoto J, Alam SM, Sato E, Sakaguchi H, Tamaya T. Role of protease activated receptor-2 in tumor advancement of ovarian cancers. Ann Oncol. 2007;18:1506–12.PubMedCrossRef Jahan I, Fujimoto J, Alam SM, Sato E, Sakaguchi H, Tamaya T. Role of protease activated receptor-2 in tumor advancement of ovarian cancers. Ann Oncol. 2007;18:1506–12.PubMedCrossRef
28.
go back to reference Albrektsen T, Sørensen BB, Hjortø GM, Fleckner J, Rao LV, Petersen LC. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 2007;5:1588–97.PubMedCrossRef Albrektsen T, Sørensen BB, Hjortø GM, Fleckner J, Rao LV, Petersen LC. Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 2007;5:1588–97.PubMedCrossRef
29.
go back to reference Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene. 2004;23:410–7.PubMedCrossRef Versteeg HH, Spek CA, Richel DJ, Peppelenbosch MP. Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene. 2004;23:410–7.PubMedCrossRef
30.
go back to reference Gessler F, Voss V, Dutzmann S, Seifert V, Gerlach R, Kogel D. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience. 2010;165:1312–22.PubMedCrossRef Gessler F, Voss V, Dutzmann S, Seifert V, Gerlach R, Kogel D. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience. 2010;165:1312–22.PubMedCrossRef
31.
go back to reference Huang F, Xiong X, Wang H, You S, Zeng H. Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. Acta Biochim Biophys Sin (Shanghai). 2010;42:325–31.CrossRef Huang F, Xiong X, Wang H, You S, Zeng H. Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. Acta Biochim Biophys Sin (Shanghai). 2010;42:325–31.CrossRef
32.
go back to reference Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109:2700–7.PubMed Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109:2700–7.PubMed
33.
go back to reference Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer. 2007;121:1949–57.PubMedCrossRef Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer. 2007;121:1949–57.PubMedCrossRef
34.
go back to reference Lakhani SA, Masud A, Kuida K, Porter Jr GA, Booth CJ, Mehal WZ, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science. 2006;311:847–51.PubMedCrossRef Lakhani SA, Masud A, Kuida K, Porter Jr GA, Booth CJ, Mehal WZ, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science. 2006;311:847–51.PubMedCrossRef
35.
go back to reference Ledgerwood EC, Morison IM. Targeting the apoptosome for cancer therapy. Clin Cancer Res. 2009;15:420–4.PubMedCrossRef Ledgerwood EC, Morison IM. Targeting the apoptosome for cancer therapy. Clin Cancer Res. 2009;15:420–4.PubMedCrossRef
Metadata
Title
Involvement of ERK1/2/NF-κB signal transduction pathway in TF/FVIIa/PAR2-induced proliferation and migration of colon cancer cell SW620
Authors
Donglin Guo
Hong Zhou
Ying Wu
Fang Zhou
Guoying Xu
Haiping Wen
Xianmei Zhang
Publication date
01-10-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0194-1

Other articles of this Issue 5/2011

Tumor Biology 5/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine